Late Boosting of the RV144 Regimen with AIDSVAX B/E and ALVAC-HIV in HIV-Uninfected Thai Volunteers, a Randomised Controlled Trial

BACKGROUND: The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX® B/E administration over six months resulted in a 31% efficacy in preventing HIV acquisition. In this trial, we assessed the immunologic impact of an additional vaccine boost to the RV144 regime...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Lancet HIV
المؤلفون الرئيسيون: Pitisuttithum, Punnee, Nitayaphan, Sorachai, Chariyalertsak, Suwat, Kaewkungwal, Jaranit, Dawson, Peter, Dhitavat, Jittima, Phonrat, Benjaluck, Akapirat, Siriwat, Karasavvas, Nicos, Wieczorek, Lindsay, Polonis, Victoria, Eller, Michael A., Pegu, Poonam, Kim, Dohoon, Schuetz, Alexandra, Jongrakthaitae, Surat, Zhou, Yingjun, Sinangil, Faruk, Phogat, Sanjay, DiazGranados, Carlos A., Tartaglia, James, Heger, Elizabeth, Smith, Kirsten, Michael, Nelson L., Excler, Jean-Louis, Robb, Merlin L., Kim, Jerome H., O’Connell, Robert J., Vasan, Sandhya
التنسيق: Artigo
اللغة:Inglês
منشور في: 2020
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7247755/
https://ncbi.nlm.nih.gov/pubmed/32035516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(19)30406-0
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة